Vandecruys
Dries Vandecruys, Leuven BE
Patent application number | Description | Published |
---|---|---|
20160066930 | ADAPTIVE SURFACE SURGICAL GUIDING APPARATUS AND SYSTEMS AND METHODS OF MANUFACTURING ADAPTIVE SURFACE SURGICAL GUIDING APPARATUS - The present application relates to adaptive surface surgical guiding apparatuses. A surgical guiding apparatus may include one or more rigid portions configured to attach to a first region of an underlying anatomical surface. The surgical guiding apparatus may further include a variable deformable portion coupled to the one or more rigid portions, the variable deformable portion configured to conform to a shape of a second region of the underlying anatomical surface to provide a stable attachment of the surgical guiding apparatus to the underlying anatomical surface. The present disclosure further provides methods for manufacturing surgical guiding apparatuses and uses of the apparatuses for placement onto an underlying anatomical surface. | 03-10-2016 |
Roger Vandecruys, Westerlo BE
Patent application number | Description | Published |
---|---|---|
20080227982 | SOLVENT FREE AMORPHOUS RAPAMYCIN - An improved process for coating implantable medical devices utilizes a number of techniques for improving the stability of therapeutic agents contained within the coating. The stability of the therapeutic agents may be improved by creating substantially solvent-free, amorphous forms of the therapeutic agents. | 09-18-2008 |
Roger Petrus Gerebem Vandecruys, Westerlo BE
Patent application number | Description | Published |
---|---|---|
20110150996 | SALT OF 4-[[4-[[4-(2-CYANOETHENYL)-2,6-DIMETHYLPHENYL]AMINO] -2-PYRIMIDINYL]AMINO]BENZONITRILE - The present invention relates to the fumarate salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile, pharmaceutical compositions comprising as active ingredient said salt and to processes for their preparation. | 06-23-2011 |
Roger Petrus Gerebern Vandecruys, Westerlo BE
Patent application number | Description | Published |
---|---|---|
20090012108 | SALT OF 4-[[4-[[4-(2-CYANOETHENYL)-2,6-DIMETHYLPHENYL]AMINO]-2-PYRIMIDINYL]AMINO]BENZONITRILE - The present invention relates to a pharmaceutical composition comprising as active ingredient the hydrochloric acid salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethyl-phenyl]amino]-2-pyrimidinyl]amino]benzonitrile and to processes for their preparation. | 01-08-2009 |
20090215804 | FUMARATE OF 4- [[4- [[4- (2-CYANOETHENYL) -2,6-DIMETHYLPHENYL)AMINO] -2-PYRIMIDINYL]AMINO]BENZONITRILE - The present invention relates to the fumarate salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile, pharmaceutical compositions comprising as active ingredient said salt and to processes for their preparation. | 08-27-2009 |
20110008434 | SALT OF 4-[[4-[[4-(2-CYANOETHENYL)-2,6-DIMETHYLPHENYL]AMINO]-2-PYRIMIDINYL- ]AMINO]BENZONITRILE - The present invention relates to a pharmaceutical composition comprising as active ingredient the hydrochloric acid salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethyl-phenyl]amino]-2-pyrimidinyl]amino]benzonitrile and to processes for their preparation. | 01-13-2011 |
20110306634 | Amorphous Salt of a Macrocyclic Inhibitor of HCV - The amorphous form of the sodium salt of the macrocyclic inhibitor of HCV of formula: | 12-15-2011 |
Roger Petrus Gerebern Vandecruys, Beerse BE
Patent application number | Description | Published |
---|---|---|
20090191266 | Pregelatinized Starch In A Controlled Release Formulation - The present invention concerns the use of pregelatinized starch to prevent dose-dumping from a hydrophilic controlled release formulation. It also concerns a hydrophilic controlled release formulation, more in particular a hydrophilic controlled release matrix formulation, and solid dosage forms prepared therefrom, preferably for once daily oral administration. The hydrophilic controlled release formulation comprises pregelatinized starch, one or more active ingredients, one or more viscous hydrophilic polymers and optionally pharmaceutically acceptable formulating agents. Preferred hydrophilic polymers include hydroxypropyl cellulose and hydroxypropyl methylcellulose. | 07-30-2009 |